Logo image
Back
Mature Follow-Up for High-Risk Stage I Non–Small-Cell Lung Carcinoma Treated With Sublobar Resection and Intraoperative Iodine-125 Brachytherapy
Journal article

Mature Follow-Up for High-Risk Stage I Non–Small-Cell Lung Carcinoma Treated With Sublobar Resection and Intraoperative Iodine-125 Brachytherapy

Athanasios Colonias, James Betler, Mark Trombetta, Ghazaleh Bigdeli, Olivier Gayou, Robert Keenan, E. Day Werts and David S. Parda
International journal of radiation oncology, biology, physics, v 79(1), pp 105-109
2011
DOI: https://doi.org/10.1016/j.ijrobp.2009.10.030
PMID: 20382483
Featured in Collection :   UN Sustainable Development Goals @ Drexel

Abstract

brachytherapy Lung cancer medically inoperable
To update the Allegheny General Hospital experience of high-risk Stage I non–small-cell lung cancer patients treated with sublobar resection and intraoperative 125I Vicryl mesh brachytherapy. Between January 5, 1996 and February 19, 2008, 145 patients with Stage I non–small-cell lung cancer who were not lobectomy candidates because of cardiopulmonary compromise underwent sublobar resection and placement of 125I seeds along the resection line. The 125I seeds embedded in Vicryl suture were attached with surgical clips to a sheet of Vicryl mesh, inserted over the target area, and prescribed to a 0.5-cm planar margin. The mean target area, total activity, number of seeds implanted, and prescribed total dose was 33.3 cm 2 (range, 18.0–100.8), 20.2 mCi (range, 11.1–29.7), 46 (range, 30–100), and 117 Gy (range, 80–180), respectively. The median length of the surgical stay was 6 days (range, 1–111), with a perioperative mortality rate of 3.4%. At a median follow-up of 38.3 months (range, 1–133), 6 patients had developed local recurrence (4.1%), 9 had developed regional failure (6.2%), and 25 had distant failure (17.2%). On multivariate analysis, no patient- or tumor-specific factors or surgical or dosimetric factors were predictive of local recurrence. The overall median survival was 30.5 months with a 3- and 5-year overall survival rate of 65% and 35%, respectively. 125I brachytherapy for high-risk, Stage I non–small-cell lung cancer after sublobar resection is well tolerated and associated with a low local failure rate.

Metrics

21 Record Views
21 citations in Web of Science
22 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Oncology
Radiology, Nuclear Medicine & Medical Imaging
Logo image